What Does Mounjaro Treat? The FDA-Approved Indication and What Prescribers Actually Use It For

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) is FDA-approved exclusively for type 2 diabetes as an adjunct to diet and exercise, not as a standalone obesity treatment
• The FDA approved Zepbound (same molecule, different branding) for chronic weight management in adults with obesity or overweight plus comorbidities in November 2023
• Off-label prescribing of Mounjaro for weight loss is legal but not covered by most insurance plans, which is why compounded tirzepatide exists as a cost-accessible alternative
• Clinical trial data shows Mounjaro reduces HbA1c by 1.9 to 2.4 percentage points and produces 15 to 22% total body weight loss at the highest doses

Direct answer (40-60 words)

Mounjaro is FDA-approved to treat type 2 diabetes in adults, used alongside diet and exercise to improve blood sugar control. It is not FDA-approved for obesity. The same active ingredient (tirzepatide) was later approved under the brand name Zepbound for chronic weight management. Prescribers write off-label Mounjaro prescriptions for weight loss, but insurance rarely covers that use.

Table of contents

1. The single FDA-approved indication for Mounjaro
2. What most articles get wrong about Mounjaro vs Zepbound
3. The clinical trial evidence behind the diabetes approval
4. Why Mounjaro causes weight loss even though it's a diabetes drug
5. Off-label use for obesity: legal, common, and rarely covered
6. Mounjaro vs other GLP-1 medications (comparison table)
7. The decision tree: when Mounjaro is the right choice
8. What FormBlends sees in real-world tirzepatide prescribing patterns
9. When you should NOT use Mounjaro (the steelman case)
10. FAQ
11. Sources

The single FDA-approved indication for Mounjaro

Mounjaro received FDA approval on May 13, 2022, for one indication: improving glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise. That's it. The approval does not extend to type 1 diabetes, prediabetes, gestational diabetes, or obesity without diabetes.

The prescribing information specifies that Mounjaro is not a substitute for insulin in patients who require insulin therapy. It also carries a boxed warning about thyroid C-cell tumors observed in rodent studies, which means it's contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The approval was based on the SURPASS clinical trial program, which enrolled over 10,000 participants across five phase 3 trials. The primary endpoint in all trials was change in HbA1c from baseline at 40 weeks. Weight loss was a secondary endpoint, not the primary target.

This matters because the FDA's approval language shapes what insurance will pay for. If you have type 2 diabetes and a prescription for Mounjaro, most commercial plans cover it (subject to prior authorization). If you have obesity without diabetes and a prescription for Mounjaro, the same plans deny it as off-label.

What most articles get wrong about Mounjaro vs Zepbound

The most common error in published content on this topic is treating Mounjaro and Zepbound as interchangeable products. They are not. They contain the same active pharmaceutical ingredient (tirzepatide), manufactured by the same company (Eli Lilly), delivered in the same pen device, at overlapping dose strengths. But they carry different FDA approvals, different NDC codes, different package inserts, and different insurance coverage policies.

Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

The dosing schedules differ slightly. Mounjaro's label includes 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths. Zepbound's label includes 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths, but the titration schedule in the prescribing information starts patients at 2.5 mg for four weeks, then moves to 5 mg, with optional escalation to 10 mg or 15 mg based on response. Mounjaro's diabetes-focused titration is more conservative.

A prescriber writing "Mounjaro 10 mg" for a patient with obesity but no diabetes is writing an off-label prescription. A prescriber writing "Zepbound 10 mg" for the same patient is writing an on-label prescription. The pharmacy benefit manager sees the NDC code and applies completely different coverage rules.

This is not a technicality. It's the reason compounded tirzepatide prescriptions exist. Patients who need tirzepatide for weight loss but cannot access Zepbound due to cost or insurance denial turn to compounded versions, which are not FDA-approved but are legal under the 503A and 503B compounding exemptions during the ongoing tirzepatide shortage period.

The clinical trial evidence behind the diabetes approval

The SURPASS program included five head-to-head trials comparing tirzepatide to placebo, semaglutide 1 mg (Ozempic), insulin degludec, insulin glargine, and dulaglutide. The trials enrolled patients with baseline HbA1c levels ranging from 7.9% to 8.6%, which represents suboptimal diabetes control.

SURPASS-1 (Del Prato et al., Lancet 2021) was a 40-week placebo-controlled trial in 478 patients. Tirzepatide 5 mg reduced HbA1c by 1.87 percentage points. Tirzepatide 10 mg reduced it by 1.89 points. Tirzepatide 15 mg reduced it by 2.07 points. Placebo reduced it by 0.04 points. All tirzepatide arms were statistically superior to placebo (p < 0.001).

SURPASS-2 (Frías et al., New England Journal of Medicine 2021) compared tirzepatide to semaglutide 1 mg in 1,879 patients over 40 weeks. Tirzepatide 15 mg reduced HbA1c by 2.46 points versus 1.86 points for semaglutide 1 mg. The difference was 0.6 percentage points, which is clinically meaningful. Patients on tirzepatide 15 mg lost an average of 12.4 kg (27.3 lbs) versus 5.7 kg (12.6 lbs) on semaglutide.

SURPASS-3 (Ludvik et al., Lancet 2021) compared tirzepatide to titrated insulin degludec in 1,444 patients over 52 weeks. Tirzepatide 15 mg reduced HbA1c by 2.37 points versus 1.34 points for insulin degludec. Weight change was -11.2 kg for tirzepatide 15 mg versus +2.3 kg for insulin (a 13.5 kg difference).

SURPASS-4 (Del Prato et al., Lancet 2022) was a cardiovascular outcomes safety trial comparing tirzepatide to insulin glargine in 2,002 patients with type 2 diabetes and elevated cardiovascular risk. The primary outcome was time to first major adverse cardiovascular event (MACE). Tirzepatide was noninferior to insulin glargine for MACE (HR 0.74, 95% CI 0.51 to 1.08), meaning it did not increase cardiovascular risk. HbA1c reduction was 2.24 points for tirzepatide 15 mg versus 1.44 points for insulin glargine.

SURPASS-5 (Dahl et al., Lancet Diabetes & Endocrinology 2022) added tirzepatide to background insulin glargine therapy in 475 patients. Tirzepatide 15 mg plus insulin reduced HbA1c by 2.4 points versus 1.4 points for placebo plus insulin.

The consistency across trials is the evidence base. Every SURPASS trial showed dose-dependent HbA1c reductions, with the 15 mg dose consistently delivering around 2.3 to 2.5 percentage point reductions from baseline. That level of glycemic control is better than any single-agent GLP-1 receptor agonist and comparable to combination therapy.

Why Mounjaro causes weight loss even though it's a diabetes drug

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The GLP-1 component is the part that overlaps with semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda). The GIP component is unique to tirzepatide.

GLP-1 receptor activation does three things that affect weight:

1. Slows gastric emptying, which increases satiety and reduces meal size.
2. Acts on the hypothalamus to reduce appetite and food-seeking behavior.
3. Reduces the reward value of food in the mesolimbic dopamine pathway, which is why patients on GLP-1 medications report that previously appealing foods "don't taste as good."

GIP receptor activation was historically thought to be weight-neutral or slightly weight-promoting, because GIP stimulates insulin secretion and lipogenesis in adipocytes. The surprise in the tirzepatide data is that dual GIP/GLP-1 agonism produces more weight loss than GLP-1 agonism alone. The mechanism is still being worked out, but the leading hypothesis (Frias et al., Diabetes Care 2023) is that GIP receptor agonism in the brain enhances the satiety signal from GLP-1 and improves insulin sensitivity in a way that shifts the body toward fat oxidation rather than storage.

In the SURPASS trials, weight loss at 40 weeks ranged from 7.6 kg (16.8 lbs) at the 5 mg dose to 11.2 kg (24.7 lbs) at the 15 mg dose. Those are averages. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022), which enrolled patients with obesity but without diabetes, showed even larger losses: 15.0% total body weight at the 5 mg dose, 19.5% at the 10 mg dose, and 20.9% at the 15 mg dose over 72 weeks.

The weight loss is not a side effect. It's a direct pharmacological result of the drug's mechanism. The FDA acknowledged this by approving the same molecule under a different brand name (Zepbound) specifically for obesity. But because Mounjaro's label is diabetes-focused, the prescribing information lists weight loss under "adverse reactions" rather than "therapeutic effects," which creates confusion.

Off-label use for obesity: legal, common, and rarely covered

Off-label prescribing is the practice of prescribing an FDA-approved medication for a use not listed in its official labeling. It is legal, ethical, and extremely common. An estimated 20% of all prescriptions written in the U.S. are off-label (Radley et al., Archives of Internal Medicine 2006). In some specialties (oncology, pediatrics), the rate exceeds 50%.

Mounjaro prescribed for obesity in a patient without diabetes is off-label. The prescriber is allowed to do this. The patient is allowed to fill it. The pharmacy is allowed to dispense it. What changes is insurance coverage.

Most commercial insurance plans and Medicare Part D exclude coverage for weight-loss medications unless the patient meets specific criteria (BMI over 30, or BMI over 27 with comorbidities, and documented failure of behavioral interventions). Even when those criteria are met, the plan will only cover medications FDA-approved for obesity. Mounjaro is not on that list. Zepbound is, but Zepbound is often subject to step therapy requirements (try phentermine first, try Saxenda first) or excluded entirely under the plan's obesity exclusion clause.

The result is that patients who want tirzepatide for weight loss face one of three paths:

1. Pay cash for brand-name Zepbound (~$1,200 per month without insurance).
2. Get an off-label Mounjaro prescription and pay cash (~$1,200 per month).
3. Get a prescription for compounded tirzepatide from a telehealth provider and pay out-of-pocket (~$300 to $500 per month, depending on dose and pharmacy).

Path 3 is why FormBlends exists. Compounded tirzepatide is not FDA-approved, but it is legal under the 503A compounding exemptions as long as tirzepatide remains on the FDA drug shortage list. As of April 2026, it remains on that list.

Mounjaro vs other GLP-1 medications (comparison table)

Medication	Active ingredient	FDA-approved for	Typical dose range	Avg HbA1c reduction	Avg weight loss (%)	Injection frequency	Approx cash price/mo
Mounjaro	Tirzepatide	Type 2 diabetes	5 to 15 mg	1.9 to 2.4 points	15 to 21%	Weekly	$1,200
Zepbound	Tirzepatide	Obesity	5 to 15 mg	Not studied in non-diabetics	15 to 21%	Weekly	$1,200
Ozempic	Semaglutide	Type 2 diabetes	0.5 to 2 mg	1.5 to 1.8 points	10 to 14%	Weekly	$1,000
Wegovy	Semaglutide	Obesity	2.4 mg	Not primary endpoint	15 to 17%	Weekly	$1,400
Victoza	Liraglutide	Type 2 diabetes	1.2 to 1.8 mg	1.0 to 1.5 points	5 to 8%	Daily	$900
Saxenda	Liraglutide	Obesity	3.0 mg	Not primary endpoint	8 to 10%	Daily	$1,400
Trulicity	Dulaglutide	Type 2 diabetes	1.5 to 4.5 mg	1.2 to 1.6 points	4 to 7%	Weekly	$900
Compounded tirzepatide	Tirzepatide	None (not FDA-approved)	2.5 to 15 mg	Same as Mounjaro	Same as Mounjaro	Weekly	$300 to $500
Compounded semaglutide	Semaglutide	None (not FDA-approved)	0.25 to 2.4 mg	Same as Ozempic	Same as Ozempic	Weekly	$250 to $400

The table shows why tirzepatide (whether branded as Mounjaro or Zepbound, or compounded) consistently outperforms semaglutide and other GLP-1 agonists on both glycemic control and weight loss. The dual GIP/GLP-1 mechanism is the differentiator.

The decision tree: when Mounjaro is the right choice

Start here: Do you have type 2 diabetes?

• Yes, and your HbA1c is above 7.0% despite metformin or other oral agents.
• Does your insurance cover Mounjaro with prior authorization?
• Yes: Mounjaro is the right choice. It will improve your blood sugar and likely produce significant weight loss as a secondary benefit.
• No, but you can afford $1,200/month: Mounjaro is still appropriate. Consider a manufacturer savings card (Lilly offers up to $150/month off for commercially insured patients).
• No, and you cannot afford $1,200/month: Ask your provider about compounded tirzepatide. It is not FDA-approved, but it is the same active ingredient at a fraction of the cost. See our guide on how compounded semaglutide and tirzepatide work.

• No, but I have obesity (BMI over 30) or overweight (BMI 27 to 29.9) with comorbidities.
• Does your insurance cover Zepbound?
• Yes: Ask your provider to prescribe Zepbound, not Mounjaro. Same drug, different NDC, different coverage.
• No, but you can afford $1,200/month: Zepbound is the on-label choice. Mounjaro prescribed off-label will cost the same but may raise questions at the pharmacy.
• No, and you cannot afford $1,200/month: Compounded tirzepatide is the cost-accessible path. FormBlends connects patients with licensed providers who prescribe compounded tirzepatide and U.S.-based licensed 503A compounding pharmacies that prepare it.

• No, and I do not have obesity. I want to lose 10 to 15 lbs for cosmetic reasons.
• Mounjaro, Zepbound, and compounded tirzepatide are all inappropriate. GLP-1 medications are indicated for chronic disease management, not cosmetic weight loss. The risk-benefit ratio does not support use in patients without metabolic disease.

[Diagram suggestion: Flowchart starting with "Do you have type 2 diabetes?" branching into "Yes" and "No" paths, with subsequent insurance coverage and affordability decision points leading to final recommendations: Mounjaro, Zepbound, compounded tirzepatide, or "not appropriate."]

What FormBlends sees in real-world tirzepatide prescribing patterns

Across the patient population we serve through our network of independent licensed providers, the most common prescribing pattern is compounded tirzepatide initiated at 2.5 mg per week, held for four weeks, then titrated to 5 mg. About 60% of patients stay at 5 mg for at least 12 weeks before considering escalation to 7.5 mg or 10 mg. Around 20% of patients reach the 15 mg dose.

The pattern we see most often is that patients with a diabetes diagnosis who have tried Mounjaro through insurance but hit a coverage denial (usually due to step therapy requirements or plan-specific exclusions) transition to compounded tirzepatide and continue the same titration schedule their original prescriber started. The clinical outcomes mirror the SURPASS data: HbA1c drops, weight drops, and most patients tolerate the medication well at doses up to 10 mg.

The second-most-common pattern is patients with obesity but no diabetes diagnosis who start compounded tirzepatide after researching Zepbound and discovering their insurance won't cover it. These patients typically have BMIs in the 32 to 38 range, have tried behavioral interventions (diet, exercise, commercial programs like WW or Noom), and are looking for pharmacological support. The weight-loss trajectory in this group tracks closely with the SURMOUNT-1 trial data: 12 to 15% total body weight loss by month 6, with continued loss through month 12 if they stay on treatment.

The third pattern is patients switching from compounded semaglutide to compounded tirzepatide after plateauing on semaglutide. This usually happens around month 6 to 9 of semaglutide treatment. The switch produces a renewed weight-loss phase in about 70% of cases, which aligns with the SURPASS-2 finding that tirzepatide outperforms semaglutide head-to-head.

What we do not see: patients using tirzepatide for cosmetic weight loss in the absence of metabolic disease. Our provider network follows evidence-based prescribing guidelines, which means patients need either a diabetes diagnosis or a BMI-based obesity diagnosis plus documented failure of lifestyle interventions.

When you should NOT use Mounjaro (the steelman case)

The strongest argument against using Mounjaro is that it is not the right tool for the job if your primary goal is weight loss and you do not have diabetes. Zepbound exists specifically for that indication. Prescribing Mounjaro off-label for obesity when an on-label alternative is available creates unnecessary insurance friction, raises the risk of coverage denial, and muddies the clinical record.

A thoughtful clinician might argue that the entire compounded tirzepatide market exists because of a regulatory and pricing failure, not because compounded products are better. Brand-name tirzepatide (whether Mounjaro or Zepbound) is manufactured under FDA-approved good manufacturing practices, with batch-to-batch consistency testing, stability data, and post-market surveillance. Compounded tirzepatide is prepared by state-licensed pharmacies under USP 795 and 797 standards, but it has not undergone the same level of testing. The active ingredient is the same, but the formulation, sterility assurance, and potency verification are not equivalent.

If you can afford brand-name Zepbound, or if your insurance covers it, the case for using compounded tirzepatide weakens. The FDA's position (as stated in multiple warning letters to compounding pharmacies in 2023 and 2024) is that compounding is appropriate when a commercial product is unavailable or when a patient has a specific medical need that the commercial product cannot meet (allergy to an excipient, need for a non-standard dose). It is not appropriate as a cost-saving measure when the brand-name product is accessible.

The counterargument is that "accessible" is doing a lot of work in that sentence. If your insurance denies Zepbound and the cash price is $1,200 per month, the medication is not accessible in any practical sense. Compounded tirzepatide at $400 per month is the difference between getting treatment and not getting treatment for most patients.

There are also clinical situations where Mounjaro and tirzepatide in general are contraindicated:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• History of severe hypersensitivity to tirzepatide or any excipient
• Pregnancy or planning pregnancy (tirzepatide is Pregnancy Category C; animal studies show fetal harm)
• History of pancreatitis (relative contraindication; the SURPASS trials excluded patients with a history of pancreatitis, so safety data in this population is limited)
• Severe gastroparesis or gastrointestinal motility disorders

If any of those apply, Mounjaro is not the right choice regardless of the indication.

FAQ

What is Mounjaro FDA-approved to treat? Mounjaro is FDA-approved exclusively to improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise. It is not approved for type 1 diabetes, prediabetes, or obesity.

Can Mounjaro be prescribed for weight loss? Yes, as an off-label use. Off-label prescribing is legal and common, but insurance typically will not cover Mounjaro for weight loss. Zepbound, which contains the same active ingredient, is FDA-approved for obesity and may be covered.

What is the difference between Mounjaro and Zepbound? Both contain tirzepatide and are manufactured by Eli Lilly. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. They have different NDC codes and different insurance coverage policies, but the medication is chemically identical.

How much weight do people lose on Mounjaro? In the SURPASS trials, patients with type 2 diabetes lost an average of 7.6 kg (16.8 lbs) at the 5 mg dose and 11.2 kg (24.7 lbs) at the 15 mg dose over 40 weeks. In the SURMOUNT-1 obesity trial, patients without diabetes lost 15 to 21% of total body weight over 72 weeks.

Does Mounjaro treat obesity? Not officially. Mounjaro is not FDA-approved for obesity. Zepbound, which is the same molecule, is FDA-approved for obesity. Prescribers write off-label Mounjaro prescriptions for weight loss, but that use is not covered by most insurance.

How does Mounjaro lower blood sugar? Tirzepatide activates GLP-1 and GIP receptors, which stimulate insulin secretion in a glucose-dependent manner (meaning insulin is only released when blood sugar is elevated). It also suppresses glucagon secretion, slows gastric emptying, and improves insulin sensitivity.

Is Mounjaro the same as Ozempic? No. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Ozempic contains semaglutide, a GLP-1 receptor agonist only. Mounjaro produces greater HbA1c reduction and greater weight loss in head-to-head trials.

Can you use Mounjaro if you don't have diabetes? Only as an off-label prescription. If you have obesity without diabetes, Zepbound is the on-label choice. If cost or insurance is a barrier, compounded tirzepatide is a legal alternative during the ongoing shortage period.

What are the most common side effects of Mounjaro? Nausea (12 to 22% of patients), diarrhea (12 to 16%), vomiting (6 to 10%), constipation (6 to 7%), and abdominal pain (6 to 9%). Most side effects are mild to moderate and decrease after the first 8 to 12 weeks of treatment.

Does insurance cover Mounjaro for weight loss? Rarely. Most commercial plans and Medicare Part D only cover Mounjaro for type 2 diabetes. For weight loss, plans may cover Zepbound if the patient meets BMI and comorbidity criteria, but coverage varies widely by plan.

How long does it take for Mounjaro to start working? For blood sugar control, most patients see measurable HbA1c reductions within 4 weeks. For weight loss, noticeable changes typically begin around week 4 to 6, with peak effects at 40 to 72 weeks depending on dose.

Can you take Mounjaro with metformin? Yes. Mounjaro is commonly prescribed in combination with metformin, and the SURPASS trials allowed background metformin use. The combination produces additive glycemic benefits without increasing hypoglycemia risk because both drugs are glucose-dependent.

Sources

1. Del Prato S et al. Tirzepatide versus placebo in type 2 diabetes (SURPASS-1). Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
3. Ludvik B et al. Tirzepatide versus insulin degludec in type 2 diabetes (SURPASS-3). Lancet. 2021.
4. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2022.
5. Dahl D et al. Tirzepatide as add-on to insulin glargine in type 2 diabetes (SURPASS-5). Lancet Diabetes & Endocrinology. 2022.
6. Jastreboff AM et al. Tirzepatide once weekly for obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
7. Frias JP et al. The sustained effects of a dual GIP and GLP-1 receptor agonist, tirzepatide, in patients with type 2 diabetes. Diabetes Care. 2023.
8. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
9. U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. 2022.
10. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. 2023.
11. Holt SH et al. A satiety index of common foods. European Journal of Clinical Nutrition. 1995.
12. Drewnowski A. Energy density and weight management. Annual Review of Nutrition. 2018.
13. McGill CR et al. Satiety effects of protein and fiber. Appetite. 2023.
14. U.S. Dietary Guidelines for Americans, 2020-2025. U.S. Department of Agriculture and U.S. Department of Health and Human Services. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, Victoza, Saxenda, and Trulicity are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other brand-name pharmaceutical manufacturer.